Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
The European Medicines Agency (EMA), headquartered in the Netherlands, plays a pivotal role in the regulation and oversight of medicinal products across Europe. Established in 1995, the agency has been instrumental in ensuring the safety and efficacy of medicines, contributing significantly to public health within the European Union and beyond.
Operating primarily within the medical, precision and optical instruments sector, the EMA focuses on the evaluation and supervision of pharmaceuticals, fostering innovation while maintaining rigorous safety standards. Its core services include scientific assessments, regulatory guidance, and post-marketing surveillance, which are essential for maintaining high-quality healthcare.
Recognised for its commitment to transparency and collaboration, the EMA has achieved notable milestones, including the rapid approval of COVID-19 vaccines, showcasing its agility in responding to public health emergencies. As a leading authority in the pharmaceutical landscape, the EMA continues to shape the future of medicine in Europe.
-7 vs industry average
European Medicines Agency’s score of 25 is lower than 43% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medical Device Manufacturing has below-average carbon intensity
The Medical Device Manufacturing industry has reduced its overall emissions by 32% since 2018
Scope 3 accounts for ••• of total emissions.
In 2023, the European Medicines Agency reported approximately 1,901,900 kg CO2e in total emissions. Their reported emissions primarily comprise Scope 3 emissions, specifically business travel, which accounted for approximately 1,682,900 kg CO2e in 2023. This marks an increase from 2022, when their total emissions were about 979,900 kg CO2e, with business travel contributing approximately 791,600 kg CO2e. In 2021, total emissions were significantly lower at about 178,500 kg CO2e, and in 2020, they were about 809,100 kg CO2e, with business travel at approximately 525,700 kg CO2e. The agency has not publicly disclosed Scope 1 or Scope 2 emissions data, and there are no specific emissions reduction targets or commitments available for the European Medicines Agency.
No climate goals have been disclosed for European Medicines Agency yet.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more